BioSpace News Archive

San Rocco Therapeutics, formerly Errant Gene Therapeutics, applauds Dr. Michel Sadelain, MD, PhD, Director of Memorial Sloan Kettering’s Center for Cell Engineering and San Rocco’s Scientific Founder as the 2021 recipient of the Outstanding Achievement Award from the American Society of Gene and Cell Therapy for discoveries to treat Sickle Cell Disease and Beta-Thalassemia.

Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin’s Lymphoma (NHL), interim clinical data expected in late 2021

Acasti Pharma Inc. announced that, on May 11, 2021, the Company received notice from the Nasdaq Listing Qualifications Department indicating that, based upon the Company’s non-compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550 as of May 10, 2021, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel.

Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced the first patient has been dosed in the randomized Phase 2b GRECO-2 trial of GC4711 in combination with stereotactic body radiation therapy in patients with locally advanced pancreatic cancer.

Preoperative Administration of ANJESO was Well Tolerated, Significantly Reduced Opioid Use and Decreased Hospital Length of Stay by Over 1 Day (28 hours) Versus Placebo

Angion Biomedica Corp, a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, provided a corporate update and reported financial results for the quarter ended March 31, 2021.

Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, announced that the first patient has been dosed in a first-in-human clinical trial of FHD-286 in metastatic uveal melanoma.

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, announced that members of its senior management team will participate in three upcoming virtual investor conferences.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced financial results for the three months ending March 31, 2021 and provided a corporate update.

Algernon Pharmaceuticals Inc. announces it has received positive feedback from the U.S. Food and Drug Administration regarding its plans to investigate AP-188, a known psychedelic compound that is part of the tryptamine family, as an adjunct to physical therapy in the rehabilitation of stroke.